{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:04:55Z","timestamp":1790751895824,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T00:00:00Z","timestamp":1542758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","gastrojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1053\/j.gastro.2018.11.035","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T05:49:05Z","timestamp":1542952145000},"page":"946-957.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis"],"prefix":"10.1053","volume":"156","author":[{"given":"William J.","family":"Sandborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7139-2916","authenticated-orcid":false,"given":"Marcoli","family":"Cyrille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Berner","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Rogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha L.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Boedigheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Abuqayyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-091X","authenticated-orcid":false,"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2018.11.035_bib1","doi-asserted-by":"crossref","first-page":"f432","DOI":"10.1136\/bmj.f432","article-title":"Ulcerative colitis","volume":"346","author":"Ford","year":"2013","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2018.11.035_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5009\/gnl14226","article-title":"Current and emerging biologics for ulcerative colitis","volume":"9","author":"Park","year":"2015","journal-title":"Gut Liver"},{"key":"10.1053\/j.gastro.2018.11.035_bib3","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ordas","year":"2012","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2018.11.035_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1517\/14656566.2015.981525","article-title":"An update on medical management on Crohn\u2019s disease","volume":"16","author":"Affronti","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1053\/j.gastro.2018.11.035_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2009.08.017","article-title":"Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up","volume":"94","author":"Devlin","year":"2010","journal-title":"Med Clin North Am"},{"key":"10.1053\/j.gastro.2018.11.035_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2018.11.035_bib7","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","article-title":"Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus","volume":"148","author":"Bressler","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.11.035_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2018.11.035_bib9","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/blood-2007-05-075176","article-title":"Lymphoma dissemination: the other face of lymphocyte homing","volume":"110","author":"Pals","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.gastro.2018.11.035_bib10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4049\/jimmunol.151.2.717","article-title":"Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with hallmarks of gut-trophism","volume":"151","author":"Schweighoffer","year":"1993","journal-title":"J\u00a0Immunol"},{"key":"10.1053\/j.gastro.2018.11.035_bib11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4049\/jimmunol.153.2.517","article-title":"Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes","volume":"153","author":"Erle","year":"1994","journal-title":"J\u00a0Immunol"},{"key":"10.1053\/j.gastro.2018.11.035_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.11.035_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/bph.12134","article-title":"Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells","volume":"169","author":"Pan","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.gastro.2018.11.035_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(13)60813-6","article-title":"Pharmacokinetics\/pharmacodynamics (PK\/PD), efficacy, and safety of AMG 181 in subjects with active, mild to moderate ulcerative colitis\u2014an initial assessment","volume":"144","author":"Pan","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.11.035_bib15","article-title":"Clinical pharmacology and safety of AMG 181, a human anti-\u03b1\u03b2 antibody for treating inflammatory bowel disease","volume":"1","author":"Pan","year":"2013","journal-title":"United European Gastroenterol J"},{"key":"10.1053\/j.gastro.2018.11.035_bib16","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/bcp.12418","article-title":"Clinical pharmacology of AMG 181, a gut-specific human anti-\u03b14\u03b27 monoclonal antibody, for treating inflammatory bowel diseases","volume":"78","author":"Pan","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.gastro.2018.11.035_bib17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/sim.5642","article-title":"Key multiplicity issues in clinical drug development","volume":"32","author":"Dmitrienko","year":"2013","journal-title":"Stat Med"},{"key":"10.1053\/j.gastro.2018.11.035_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/gut.40.2.241","article-title":"Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation","volume":"40","author":"Meenan","year":"1997","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.11.035_bib19","unstructured":"Yu Z, Sullivan BA, Rees WA, et\u00a0al. Pharmacokinetics (PK), pharmacodynamics (PD), and safety profile of AMG 181 (MEDI7183) in healthy Japanese are not different from Caucasian subjects. Presented at: Annual Meeting of the American College of Clinical Pharmacology;\u00a02013."},{"key":"10.1053\/j.gastro.2018.11.035_bib20","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.11.035_bib21","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/S0016-5085(12)60607-6","article-title":"943b Induction therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial","volume":"142","author":"Feagan","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.11.035_bib22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508518352831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508518352831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T12:03:56Z","timestamp":1694088236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508518352831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0016508518352831"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2018.11.035","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2018.11.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}